Sean Parker-backed cell therapy startup ArsenalBio plucks Merck VP as new CSO

Zachary Brennan

Senior Editor

Merck’s immuno-oncology superstar Nicholas Haining has been appointed CSO at ArsenalBio, which is working on an approach to programmable cell therapies.

The addition of a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sean Parker-backed cell therapy startup ArsenalBio plucks Merck VP as new CSO

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Sean Park­er-backed cell ther­a­py start­up Ar­se­nal­Bio plucks Mer­ck VP as new CSO

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Sean Parker-backed cell therapy startup ArsenalBio plucks Merck VP as new CSO